MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
LENSAR Accounts Payables 2011-2026 | LNSR
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables LENSAR
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 M | 4.01 M | 5.42 M | 2.69 M | 2.48 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6 M | 2.48 M | 4.12 M |
Quarterly Accounts Payables LENSAR
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.8 M | 11.3 M | 7.75 M | 6 M | 3.87 M | 4.12 M | - | 4.01 M | 3.94 M | 4.62 M | 4.92 M | 5.42 M | 3.51 M | 4.19 M | 2.85 M | 2.69 M | 2.4 M | 2.86 M | 1.7 M | 2.48 M | 2.48 M | 2.48 M | 2.48 M | 1.58 M | 1.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.8 M | 1.58 M | 4.33 M |
Accounts Payables of other stocks in the Medical devices industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alphatec Holdings
ATEC
|
40.9 M | $ 11.75 | -3.29 % | $ 1.76 B |  USA |
 |
Axonics Modulation Technologies
AXNX
|
9.07 M | - | - | $ 3.31 B | USA |
 |
Delcath Systems
DCTH
|
2.66 M | $ 8.98 | -1.32 % | $ 322 M | USA |
 |
Aziyo Biologics
AZYO
|
4.79 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
2.76 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
1.21 M | - | 3.58 % | $ 2.21 M | USA |
 |
Second Sight Medical Products
EYES
|
817 K | - | -0.97 % | $ 54.4 M | USA |
 |
FONAR Corporation
FONR
|
1.55 M | $ 18.41 | 0.38 % | $ 121 M | USA |
 |
Conformis
CFMS
|
4.16 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
14.4 M | - | 0.15 % | $ 844 M | USA |
 |
Inogen
INGN
|
20.3 M | $ 6.32 | -2.02 % | $ 168 M | USA |
 |
Apollo Endosurgery
APEN
|
7.42 M | - | - | $ 475 M | USA |
 |
IRIDEX Corporation
IRIX
|
4.5 M | $ 1.35 | - | $ 21.8 M | USA |
 |
IRadimed Corporation
IRMD
|
1.82 M | $ 100.97 | 1.78 % | $ 1.28 B | USA |
 |
Avinger
AVGR
|
777 K | - | -20.74 % | $ 369 K | USA |
 |
LivaNova PLC
LIVN
|
97.2 M | $ 62.4 | -1.33 % | $ 3.4 B |  Britain |
 |
AxoGen
AXGN
|
2.89 M | $ 32.61 | 2.71 % | $ 1.5 B | USA |
 |
CONMED Corporation
CNMD
|
93.6 M | $ 36.56 | -0.19 % | $ 1.13 B | USA |
 |
Medtronic PLC
MDT
|
2.45 B | $ 86.58 | -0.68 % | $ 111 B | USA |
 |
NanoVibronix
NAOV
|
47 K | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
2.67 M | $ 24.7 | 0.86 % | $ 209 M | USA |
 |
InspireMD
NSPR
|
1.26 M | $ 1.79 | 3.47 % | $ 115 M |  Israel |
 |
Orthofix Medical
OFIX
|
58.4 M | $ 11.72 | -1.26 % | $ 464 M |  Curacao |
 |
Cytosorbents Corporation
CTSO
|
3.34 M | $ 0.7 | 3.3 % | $ 38.1 M | USA |
 |
Aethlon Medical
AEMD
|
535 K | $ 2.16 | -6.09 % | $ 3.37 M | USA |
 |
BIOLASE
BIOL
|
6.06 M | - | -13.19 % | $ 166 K | USA |
 |
Penumbra
PEN
|
34.7 M | $ 334.17 | -0.41 % | $ 13 B | USA |
 |
AdaptHealth Corp.
AHCO
|
352 M | $ 11.48 | 10.7 % | $ 1.55 B | USA |
 |
Myomo
MYO
|
1.51 M | $ 0.7 | -1.83 % | $ 29.3 M | USA |
 |
Insulet Corporation
PODD
|
75 M | $ 225.5 | -0.7 % | $ 15.9 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
2.21 M | $ 2.4 | -1.64 % | $ 141 M | Israel |
 |
Invacare Corporation
IVC
|
105 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
5.71 M | $ 3.91 | 4.83 % | $ 146 M |  France |
 |
Quanterix Corporation
QTRX
|
13.6 M | $ 3.82 | -3.05 % | $ 163 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
18.8 M | $ 15.91 | -3.4 % | $ 373 M | USA |
 |
Outset Medical
OM
|
554 K | $ 3.53 | -2.35 % | $ 53.7 K | USA |